Gene · 23091
Papers1,599
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
441 to 460 of 1,599
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Comprehensive analysis of the prognostic impact and immune implication of KIAA1429 in lung adenocarcinoma. | Cancer Innov | 2022 | 38089085 | PubTator, text mining | PubMed |
| Correlative Study on the Relationship between the Expression of m6a-Related Genes and the Prognosis and Immunotherapy of Soft Tissue Sarcoma. | Biomed Res Int | 2022 | 38024481 | PubTator, text mining | PubMed |
| Research Progress on N6-adenosylate Methylation RNA Modification in Heart Failure Remodeling. | J Transl Int Med | 2022 | 36860637 | PubTator, text mining | PubMed |
| N6-methyladenosine modulation classes and immune microenvironment regulation in ischemic stroke. | Front Mol Neurosci | 2022 | 36762188 | PubTator, text mining | PubMed |
| RNA modification writers pattern in relation to tumor microenvironment and prognosis in prostate cancer. | Front Genet | 2022 | 36744180 | PubTator, text mining | PubMed |
| Clinical and molecular significance of the RNA m6A methyltransferase complex in prostate cancer. | Front Genet | 2022 | 36733939 | PubTator, text mining | PubMed |
| Angiogenesis-related gene signatures reveal the prognosis of cervical cancer based on single cell sequencing and co-expression network analysis. | Front Cell Dev Biol | 2022 | 36712973 | PubTator, text mining | PubMed |
| Identification and validation of signature for prognosis and immune microenvironment in gastric cancer based on m6A demethylase ALKBH5. | Front Oncol | 2022 | 36686788 | PubTator, text mining | PubMed |
| Genes related to N6-methyladenosine in the diagnosis and prognosis of idiopathic pulmonary fibrosis. | Front Genet | 2022 | 36685949 | PubTator, text mining | PubMed |
| Construction and validation of a novel ferroptosis-related signature for evaluating prognosis and immune microenvironment in ovarian cancer. | Front Genet | 2022 | 36685851 | PubTator, text mining | PubMed |
| Identification and Validation of Three m6A Regulators: FTO, HNRNPC, and HNRNPA2B1 as Potential Biomarkers for Endometriosis. | Genes (Basel) | 2022 | 36672827 | PubTator, text mining | PubMed |
| Integrated Profiles of Transcriptome and mRNA m6A Modification Reveal the Intestinal Cytotoxicity of Aflatoxin B1 on HCT116 Cells. | Genes (Basel) | 2022 | 36672820 | PubTator, text mining | PubMed |
| Bioinformatics analysis of the correlation between m6A RNA methylation regulators and the immune infiltration and prognosis of bladder cancer. | Ann Transl Med | 2022 | 36660722 | PubTator, text mining | PubMed |
| The landscape of m6A regulators in esophageal cancer: molecular characteristics, immuno-oncology features, and clinical relevance. | Ann Transl Med | 2022 | 36660671 | PubTator, text mining | PubMed |
| N6-methyladenosine methylation-related genes YTHDF2, METTL3, and ZC3H13 predict the prognosis of hepatocellular carcinoma patients. | Ann Transl Med | 2022 | 36660669 | PubTator, text mining | PubMed |
| Effect of N6-methyladenosine (m6A) regulator-related immunogenes on the prognosis and immune microenvironment of breast cancer. | Transl Cancer Res | 2022 | 36644186 | PubTator, text mining | PubMed |
| A lncRNA-immune checkpoint-related gene signature predicts metastasis-free survival in prostate adenocarcinoma. | Transl Androl Urol | 2022 | 36632155 | PubTator, text mining | PubMed |
| Constructing and validating of m6a-related genes prognostic signature for stomach adenocarcinoma and immune infiltration: Potential biomarkers for predicting the overall survival. | Front Oncol | 2022 | 36620557 | PubTator, text mining | PubMed |
| Dynamic regulation and key roles of ribonucleic acid methylation. | Front Cell Neurosci | 2022 | 36601431 | PubTator, text mining | PubMed |
| Interplay of four types of RNA modification writers revealed distinct tumor microenvironment and biological characteristics in pancreatic cancer. | Front Immunol | 2022 | 36601127 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/23091/papers?page=23